Matthias Schieker | Vice President, Sr. Distinguished Fellow – Translational Medicine
Novartis

28 years after I graduated from medical school I am a physician-scientist, board-certified surgeon, emergency physician, osteologist, former Professor of Regenerative Medicine, founder, innovator, teacher, key-note speaker, strategic advisor, reviewer, strategic workstream lead, and chair of various boards. My vision is to develop drugs based on digital twin models, personalized value and outcome-based strategies, leveraging big data analytics, AI based clustering and prediction modeling as well as innovative imaging endpoints. As a leader in Pharma, Biotech and Academia with experience spanning from basic science, clinical research, academic medicine/clinical practice, early and late stage clinical development, AI-based phenotyping/prediction modeling, digital image analysis, new endpoint development, drug safety, BD&L, medical affairs, medical communication, guideline committees, health authority (FDA, EMA, PMDA) and HTA (GBA) consultations, pre- and post market activities including launch preparation, I have worked on small molecules, biologics, gene therapies and biosimilars in various therapeutic areas (oncology, immunology, rheumatology, dermatology, cardiovascular, renal): E.g., denosumab, evolocumab, brodalumab, panitumomab, blinatumomab, pegfilgrastim, canakinumab, secukinumab, and compounds addressing key immunology pathways, e.g., IL-1, IL-17, JAK/STAT, inflammasome/NLRP3,
and evaluated multiple external opportunities in immunology, rheumatology, dermatology, neurology, and musculoskeletal diseases.